PortViewPortView
ADARx Pharmaceuticals logo

ADARx Pharmaceuticals (ADRX) Stock Analysis

NASDAQHealthcareBiotechnology

$17.77-2.00%
1-year price historyRange $17.13 – $20.64
52-week range$17.77
$16.61$23.21

Track ADRX in your portfolio for free · Portfolio tracker

What ADARx Pharmaceuticals does

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Key metrics

Market cap
$1.90B
P/E (TTM)
-15.32
EPS (TTM)
$-1.16
Beta
0.00
50-day avg
$18.29
200-day avg
$18.29
52-week high
$23.21
52-week low
$16.61
CEO
Zhen Li

ETFs linked to ADRX

Broad-market and Healthcare sector ETFs an investor holding ADARx Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ADRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ADRX in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for ADARx Pharmaceuticals?
ADARx Pharmaceuticals trades under the ticker ADRX on NASDAQ.
Which exchange is ADRX listed on?
ADRX is listed on NASDAQ.
What sector does ADARx Pharmaceuticals operate in?
ADARx Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ADRX in a portfolio?
PortView shows ADRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.